Biotech drugmaker ImClone Systems Inc. said Wednesday that it named financier Carl Icahn as its new chairman and reported its third-quarter earnings rose 85 percent— results that far exceeded ...

Eli Lilly bought ImClone Systems in 2008, after a bidding war with Bristol-Myers Squibb. It paid $6.5 billion not only for Imclone's Erbitux, but also experimental drugs. Today, that buy looks ...

Sam Waksal, the former chief executive of ImClone Systems Inc, whose insider trading scam sent him and Martha Stewart to prison, on Monday announced an acquisition meant to catapult him back into ...

Imclone Systems biopharmaceutical manufacturing facility in Branchburg was approved by the FDA in July 2002, according to pharmaceutical-technology.com.

Eli Lilly & Co.'s winning bid of more than $6 billion for cancer drugmaker ImClone Systems means a billion-dollar payday for former rival bidder Bristol-Myers and vindication for corporate raider ...

It's official: Eli Lilly is the highest bidder for ImClone Systems. The drugmaker has agreed to pay $6.5 billion cash for ImClone, outbidding Bristol-Myers Squibb by more than 10 percent. And the ...

INDIANAPOLIS — Eli Lilly & Co. has agreed to spend more than $6 billion to fortify its cancer treatment portfolio by acquiring the biotechnology firm ImClone Systems Inc. in a deal that tops ...

NEW YORK — A rebuffed Bristol-Myers Squibb Co. is trying to entice the shareholders of biotech company ImClone Systems Inc. with a sweetened $62-per-share tender offer. Bristol-Myers on Monday ...

Bristol-Myers Squibb is seeking to acquire the biopharmaceutical company ImClone Systems (New York) for $4.5 billion or $60 per share. BMS currently holds a 17% stake in ImClone.

NEW YORK — ImClone Systems’ board of directors said Monday cancer-drug partner Bristol-Myers Squibb’s $4.5 billion buyout offer “substantially undervalues” the company, with Chairman ...